Search results for "Adverse effect"

showing 10 items of 1065 documents

Associations between air pollution and pediatric eczema, rhinoconjunctivitis and asthma: A meta-analysis of European birth cohorts

2020

Background: Uncertainly continues to exist regarding the role of air pollution on pediatric asthma and allergic conditions, especially as air pollution levels have started to decrease in recent decades. Objective: We examined associations of long-term air pollution levels at the home address with pediatric eczema, rhinoconjunctivitis and asthma prevalences in five birth cohorts (BIB, EDEN, GASPII, RHEA and INMA) from seven areas in five European countries. Methods: Current eczema, rhinoconjunctivitis and asthma were assessed in children aged four (N = 6527) and eight years (N = 2489). A multi-morbidity outcome (≥2 conditions versus none) was also defined. Individual outdoor levels of nitrog…

010504 meteorology & atmospheric sciencesAir pollution exposureAir pollutionEczemacross-sectional studies010501 environmental sciencesmedicine.disease_cause01 natural sciences[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractRhinoconjunctivitisEnvironmental healthAir PollutionmedicineAir Pollutants/toxicityHumans[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyAdverse effectChildlcsh:Environmental sciences0105 earth and related environmental sciencesGeneral Environmental ScienceAsthmaRhinitislcsh:GE1-350Pediatric[SDV.EE.SANT]Life Sciences [q-bio]/Ecology environment/Health[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/PediatricsAir PollutantsOdds ratioEnvironmental Exposuremedicine.diseaseConjunctivitisConfidence intervalAsthma3. Good healthEurope13. Climate actionMeta-analysis[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieParticulate MatterConjunctivitis/epidemiologyBirth cohortEnvironmental SciencesBirth cohort
researchProduct

Monitoring B-cell repopulation after depletion therapy in neurologic patients.

2017

ObjectiveTo determine the factors that influence B-cell repopulation after B-cell depletion therapy in neurologic patients and derive recommendations for monitoring and dosing of patients.MethodsIn this study, we determined the association of body surface area (BSA; calculated by body weight and height with the Dubois formula), sex, pretreatment therapy, age, CSF data, and white blood cell counts with the risk and timing of B-cell repopulation, defined as 1% CD19+ cells (of total lymphocytes), following 87 B cell–depleting anti-CD20 treatment cycles of 45 neurologic patients (28 women; mean age ± SD, 44.5 ± 15.0 years).ResultsPatients with a larger BSA had a higher probability to reach 1% C…

0301 basic medicine40medicine.medical_specialty41132LymphocyteUrologyCD19Article03 medical and health sciences0302 clinical medicineWhite blood cellMedicineDosingAdverse effectB cellBody surface areabiologybusiness.industry14323030104 developmental biologymedicine.anatomical_structureNeurologybiology.proteinRepopulationNeurology (clinical)business030217 neurology & neurosurgeryNeurology(R) neuroimmunologyneuroinflammation
researchProduct

Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease

2019

Background and Objective: Only a few studies have reported long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still disease (AOSD). Herein we report on the effectiveness of anakinra (ANA), expressed in terms of drug retention rate (DRR), and evaluate the predictive factors of drug survival in a cohort of patients with sJIA and AOSD. Patients and Methods: This is a multicenter study reviewing retrospectively the medical records from 61 patients with sJIA and 76 with AOSD, all treated with ANA in 25 Italian tertiary referral centers. Results: The cumulative retention rate of ANA at 12-, 24-, 48-, and 60-month of follow-up was 7…

0301 basic medicineAdult onset Still diseasemedicine.medical_specialtyArthritisStill DiseaseAdult onset Still disease; Anakinra; Drug retention rate; Innovative biotechnologies; Interleukin 1-beta; Personalized medicine; Systemic juvenile idiopathic arthritis03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E Specialisticaanakinra interleukin 1-beta innovative biotechnologies drug retention rate systemic juvenile idiopathic arthritis adult onset Still disease personalized medicineSystemic juvenile idiopathic arthritisInternal medicinemedicinePharmacology (medical)Adverse effectOriginal ResearchPharmacologyAnakinrabusiness.industryHazard ratiolcsh:RM1-950Innovative biotechnologiesmedicine.diseaseDrug retention ratePersonalized medicineConfidence intervalAdult onset Still disease Anakinra Drug retention rate Innovative biotechnologies Interleukin 1-beta Personalized medicine Systemic juvenile idiopathic arthritisDiscontinuation030104 developmental biologylcsh:Therapeutics. PharmacologyAnakinraInnovative biotechnologie030220 oncology & carcinogenesisCohortInterleukin 1-betabusinessmedicine.drug
researchProduct

Antiepileptic drug reduction and increased risk of stimulation-evoked focal to bilateral tonic-clonic seizure during cortical stimulation in patients…

2017

Introduction: Stimulation-evoked focal to bilateral tonic-clonic seizure (FBTCS) can be a stressful and possibly harmful adverse event for patients during cortical stimulation (CS). We evaluated if drug load reduction of anti epileptic drugs (AEDs) during CS increases the risk of stimulation-evoked FBTCS. Material and methods: In this retrospective cohort study, we searched our local database for patients with drug resistant epilepsy who underwent invasive video-EEG monitoring and CS in the University Hospital la Fe Valencia from January 2006 to November 2016. The AED drug load was calculated with the defined daily dose. We applied a uni- and multivariate logistic regression model to estima…

0301 basic medicineAdultMalemedicine.medical_specialtyDrug Resistant EpilepsyNeurologyAdolescentDrug-Related Side Effects and Adverse ReactionsStimulation03 medical and health sciencesBehavioral NeuroscienceEpilepsy0302 clinical medicineEpilepsy surgerySeizuresmedicineOdds RatioHumansEpilepsy surgeryAdverse effectRetrospective Studiesbusiness.industryRetrospective cohort studyElectroencephalographyOdds ratioMiddle Agedmedicine.diseaseElectric Stimulation030104 developmental biologyDefined daily doseLogistic ModelsTreatment OutcomeNeurologyElectrical stimulationWithdrawalAnesthesiaDefined daily doseAnticonvulsantsEpilepsy GeneralizedFemaleNeurology (clinical)Epilepsies PartialEpilepsy Tonic-ClonicSafetybusinessGeneralized tonic-clonic seizure030217 neurology & neurosurgeryEpilepsybehavior : EB
researchProduct

Lacosamide in patients with temporal lobe epilepsy: An observational multicentric open-label study.

2016

Abstract Purpose The aim of this study was to evaluate the efficacy and tolerability of lacosamide (LCM) both as add-on therapy and monotherapy in patients with temporal lobe epilepsy (TLE) based on an observational, prospective, multicenter study. Methods We enrolled 100 patients (mean age: 43.4 ± 12.53 years, 57 females) with nonlesional TLE and TLE with hippocampal sclerosis (HS) that did not respond to the first drug and who were referred to epilepsy centers of the University of Catanzaro, University of Palermo, IRCSS Neuromed of Pozzilli, and Otto-von-Guericke University of Magdeburg. In this open-label, multicenter trial, patients were initiated on oral LCM as add-on therapy to first …

0301 basic medicineAdultMalemedicine.medical_specialtyLacosamideCohort Studies03 medical and health sciencesBehavioral NeuroscienceEpilepsyYoung Adult0302 clinical medicineLacosamideMulticenter trialInternal medicineAcetamidesMedicineHumansProspective StudiesAdverse effectProspective cohort studyHippocampal sclerosisbusiness.industryMiddle Agedmedicine.diseaseMagnetic Resonance Imaging030104 developmental biologyNeurologyTolerabilityEpilepsy Temporal LobeAnesthesiaConcomitantAnticonvulsantsDrug Therapy CombinationFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugFollow-Up StudiesEpilepsybehavior : EB
researchProduct

Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodyspla…

2017

This is an observational-retrospective study comparing the real-world outcomes associated with posaconazole vs. itraconazole as prophylaxis treatments. Two hundred and ninety-three patient admissions attributable to 174 patients were included in the study. Patients were treated with itraconazole (n = 114 admissions; 39%) or posaconazole (n = 179; 61%). Antifungal prophylaxis failure (APF) due to treatment-related adverse events (in 34 out of 293 patient admissions; 11.6%) was more frequent in the posaconazole group (6.1% vs. 15.1%; P = 0.024). There were 9 patient admissions for episodes of APF due to probable/proven breakthrough fungal infection (primary endpoint): 6 and 3 in the itraconaz…

0301 basic medicineAdultMalemedicine.medical_specialtyPosaconazoleAntifungal AgentsDrug-Related Side Effects and Adverse ReactionsItraconazole030106 microbiologyDermatologyNeutropenia03 medical and health sciencesInternal medicinemedicineClinical endpointHumansIn patientTreatment FailureAdverse effectAgedRetrospective StudiesInvasive Pulmonary Aspergillosisbusiness.industryMyelodysplastic syndromesGeneral MedicineMiddle AgedTriazolesmedicine.diseaseSurgeryClinical trialLeukemia Myeloid AcuteInfectious DiseasesMyelodysplastic SyndromesFemalePre-Exposure ProphylaxisItraconazolebusinessInvasive Fungal Infectionsmedicine.drugMycoses
researchProduct

Double-Blind, Placebo-Controlled, Randomized Trial of Selenium in Graves Hyperthyroidism.

2017

Abstract Context Supplemental selenium (Se) may affect the clinical course of Graves disease (GD). Objective Evaluate efficacy of add-on Se on medical treatment in GD. Design Double-blind, placebo-controlled, randomized supplementation trial. Setting Academic endocrine outpatient clinic. Patients Seventy untreated hyperthyroid patients with GD. Intervention Additionally to methimazole (MMI), patients received for 24 weeks either sodium selenite 300 µg/d po or placebo. MMI was discontinued at 24 weeks in euthyroid patients. Main Outcome Measures Response rate (week 24), recurrence rate (week 36), and safety. Results A response was registered in 25 of 31 patients (80%) and in 27 of 33 (82%) a…

0301 basic medicineAdultMalemedicine.medical_specialtySide effectEndocrinology Diabetes and MetabolismGraves' diseaseClinical Biochemistry030209 endocrinology & metabolismContext (language use)PlaceboBiochemistryHyperthyroidismlaw.inventionPlacebos03 medical and health sciencesSelenium0302 clinical medicineEndocrinologyRandomized controlled trialDouble-Blind MethodlawRecurrenceInternal medicineMedicineOutpatient clinicHumansEuthyroidAdverse effectbusiness.industryBiochemistry (medical)Middle Agedmedicine.diseaseGraves Disease030104 developmental biologyEndocrinologyTreatment OutcomeDietary SupplementsFemalebusinessThe Journal of clinical endocrinology and metabolism
researchProduct

Adult rat myelin enhances axonal outgrowth from neural stem cells.

2018

Axon regeneration after spinal cord injury (SCI) is attenuated by growth inhibitory molecules associated with myelin. We report that rat myelin stimulated the growth of axons emerging from rat neural progenitor cells (NPCs) transplanted into sites of SCI in adult rat recipients. When plated on a myelin substrate, neurite outgrowth from rat NPCs and from human induced pluripotent stem cell (iPSC)-derived neural stem cells (NSCs) was enhanced threefold. In vivo, rat NPCs and human iPSC-derived NSCs extended greater numbers of axons through adult central nervous system white matter than through gray matter and preferentially associated with rat host myelin. Mechanistic investigations excluded …

0301 basic medicineAgingNeuronalNudeMessengerNeurodegenerativeInbred C57BLRegenerative MedicineMedical and Health SciencesMyelinMiceNeural Stem CellsStem Cell Research - Nonembryonic - HumanCyclic AMPAxonPhosphorylationGray MatterInduced pluripotent stem cellExtracellular Signal-Regulated MAP KinasesSpinal Cord InjuryMyelin SheathInbred F344Neuronal growth regulator 1Stem Cell Research - Induced Pluripotent Stem Cell - HumanChemistryGeneral MedicineBiological SciencesWhite MatterNeural stem cellCell biologymedicine.anatomical_structureSpinal Cord5.1 PharmaceuticalsNeurologicalFemaleStem Cell Research - Nonembryonic - Non-HumanDevelopment of treatments and therapeutic interventionsPhysical Injury - Accidents and Adverse EffectsNeuriteCell Adhesion Molecules NeuronalCentral nervous systemNeuronal OutgrowthArticleWhite matter03 medical and health sciencesRats NudemedicineAnimalsHumansRNA MessengerStem Cell Research - Embryonic - HumanTraumatic Head and Spine InjuryTransplantationStem Cell Research - Induced Pluripotent Stem CellNeurosciencesStem Cell ResearchRats Inbred F344AxonsRatsMice Inbred C57BL030104 developmental biologynervous systemChondroitin Sulfate ProteoglycansRNACell Adhesion Molecules
researchProduct

Frailty as a predictor of adverse outcomes in hospitalized older adults: A systematic review and meta-analysis.

2019

Frailty syndrome is prevalent among hospitalized older adults as are the occurrence of adverse outcomes. This systematic review and meta-analysis investigated whether frailty in older adults at hospital admission predicts adverse outcomes. Manual (ProQuest, conferences annals and references) and electronic searches (PUBMED, EMBASE, Web of Science, Lilacs, CINAHL, PsycINFO and Google Scholar) were performed. We included prospective studies of hospitalized older adults. Primary outcomes were functional decline at hospital discharge and mortality after discharge. Other data were considered secondary outcomes. Methodological quality was evaluated by the Quality Assessment Tool for Observational…

0301 basic medicineAgingPediatricsmedicine.medical_specialtyFrail ElderlyFrailty syndromeAdverse effectBiochemistry03 medical and health sciences0302 clinical medicineRisk FactorsPrevalenceMedicineHumansRisk factorOlder adultMortalityAdverse effectProspective cohort studyMolecular BiologyGeriatric AssessmentAgedAged 80 and overFrailtybusiness.industryLength of Staymedicine.disease030104 developmental biologyNeurologyMeta-analysisRelative riskCohortObservational studyFemalebusiness030217 neurology & neurosurgeryBiotechnologyAgeing research reviews
researchProduct

SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell …

2021

Syndrome coronavirus 2 (SARS-CoV-2) pandemic is causing a second outbreak significantly delaying the hope for the virus’ complete eradication. In the absence of effective vaccines, we need effective treatments with low adverse effects that can treat hospitalized patients with COVID-19 disease. In this study, we determined the existence of SARS-CoV-2-specific T cells within CD45RA– memory T cells in the blood of convalescent donors. Memory T cells can respond quickly to infection and provide long-term immune protection to reduce the severity of COVID-19 symptoms. Also, CD45RA– memory T cells confer protection from other pathogens encountered by the donors throughout their life. It is of vita…

0301 basic medicineCD3Secondary infectionDiseasemedicine.disease_causeVirusCell therapyCell and Developmental Biology03 medical and health sciences0302 clinical medicinememory T cells (Tmem)MedicineAdverse effectlcsh:QH301-705.5Original ResearchCoronavirusbiologybusiness.industryEffectorCOVID-19Cell BiologylymphopeniaBiobankbiobank030104 developmental biologylcsh:Biology (General)030220 oncology & carcinogenesisImmunologybiology.proteinadoptive cell therapy (ACT)businessCD8Developmental Biology
researchProduct